- Details
- Rashid Sayyid discusses a systematic review and meta-analysis on combining PARP inhibitors with AR signaling inhibitors in mCRPC treatment, published in BJU International. The study, which synthesized data from three significant trials, sought to improve survival across all patients, focusing on those without specific biomarkers. Results showed a 35% reduction in radiographic progression-free surv...
|
- Details
- Alicia Morgans interviews Alan Bryce about his session on radiopharmaceutical therapies for mCRPC with bone metastases, focusing on the decision-making between radium-223 and lutetium-177. Dr. Bryce explains the session aimed at practical clinical decision-making, emphasizing the underlying science of radiopharmaceuticals, including the distinctions between alpha and beta emitters and their target...
|
- Details
- Alicia Morgans interviews Maha Hussain about the BRCAAWAY trial, a phase two study exploring the efficacy of combining abiraterone and olaparib for patients with metastatic castration-resistant prostate cancer harboring BRCA1, BRCA2, or ATM mutations. Highlighting the journey from the inception of the trial to its execution, Hussain delves into the rigorous selection criteria and the strategic des...
|
- Details
- Alicia Morgans interviews Neeraj Agarwal about the CONTACT-02 trial, a phase III study that explores the combination of cabozantinib and atezolizumab in patients with metastatic castrate-resistant prostate cancer (mCRPC) who have progressed on one novel hormonal therapy (NHT). This trial, which focuses on patients with extrapelvic soft tissue metastasis, has shown a significant reduction in the ri...
|
- Details
- Alicia Morgans interviews Matthew Rettig about the evolving treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) within the veterans' healthcare system. Dr. Rettig highlights the VA's infrastructure that supports comprehensive care, including genetic analyses, access to a wide range of medications, and innovative telehealth programs that extend expert care to veterans in...
|
- Details
- Evan Yu and Oliver Sartor discuss the VISION trial's exploration of predictive and prognostic markers in the treatment of prostate cancer with Lutetium-PSMA-617. Sartor clarifies the distinction between predictive and prognostic markers, emphasizing the trial's focus on baseline markers and their association with treatment outcomes. The conversation highlights the importance of PSMA PET scans in p...
|
- Details
- Zachary Klaassen interviews Henrik Grönberg about the ProBio trial, presented at ESMO 2023. The ProBio trial, designed in 2019, is a platform trial aimed at determining the optimal treatment sequence for metastatic prostate cancer and identifying predictive biomarkers for treatment efficacy. Unique to ProBio is its use of circulating tumor DNA as a biomarker for assigning patients to experimental...
|
- Details
- Jacob Orme and Emmanuel Antonarakis discuss their study on the use of PARP inhibitors in metastatic prostate cancer patients with BRCA2 and SPOP mutations. Dr. Antonarakis shares the study's genesis, rooted in his clinical observation of exceptional responses to PARP inhibitors in patients with these mutations. The study, involving 131 patients across 13 international sites, reveals that patients...
|
- Details
- Kevin Kelly discusses a groundbreaking approach to prostate cancer treatment with Alicia Morgans. He presents Xaluritamig (AMG 509) a novel bi-specific antibody targeting the STEAP1 protein, prevalent in prostate cancer cells. This innovative therapy, a form of biTE therapy, is designed to attract T-cells for targeted cytotoxicity. In a phase one trial involving advanced prostate cancer patients w...
|
- Details
- Zach Klaassen speaks with Dan George about a key study comparing Enzalutamide (Enza) and Abiraterone (Abi) in pre-chemotherapy metastatic castration-resistant prostate cancer (mCRPC). This study addresses a significant gap in head-to-head clinical trials for these drugs. Dr. George discusses various data sources, including the French National Database, Flatiron, and VA data, all indicating a survi...
|
